FDA Approval of Nirogacestat Introduces First Systemic SOC Therapy for Desmoid Tumors
December 1st 2023
Mrinal M. Gounder, MD, discusses the rationale for investigating nirogacestat in the DeFi trial, highlights patient-reported outcomes with the agent in this study, and discusses potential next steps for better utilizing T2-weighted magnetic resonance imaging in addition to RECIST criteria when assessing tumor volume and dimensions in desmoid tumors.